SCHEMBL643449

SCHEMBL643449

CCC(C)OP(=O)(O)C(F)(F)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.50
ACP3 P15309 1/20 0.41
PSMB1 P20618 1/20 0.40
PSMB5 P28074 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
MMP2 P08253 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
PGK1 P00558 2/20 0.38
PGK2 P07205 2/20 0.38
ATM Q13315 1/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
CACNA1C Q13936 1/20 0.38
RECQL P46063 1/20 0.38
PTPN5 P54829 1/20 0.38
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL641569 0.89 PTPRC (0.48) PTPRCACP3PSMB1PSMB5CA12
SCHEMBL642521 0.85 ALDH1A1 (0.42) CA12CA1MMP2AKR1C3PGK1
SCHEMBL642868 0.81 PGK1 (0.42) ACP3PGK1PGK2PTPN5
SCHEMBL643542 0.78 NPSR1 (0.43) CYP2C9CYP2C19CYP1A2KMT2ARAB9A
SCHEMBL642081 0.78 CA12 (0.40) PSMB5CA12CA1MMP2PGK1
SCHEMBL4159264 0.77 GRM8 (0.49) PTPRCACP3CA12CA1MMP2
SCHEMBL917313 0.77 NPSR1 (0.46) PTPRCACP3CA12CA1MMP2
SCHEMBL643469 0.76 ALDH1A1 (0.40) CA12CA1MMP2AKR1C3PGK1
SCHEMBL643448 0.75 PTPRC (0.50) PTPRCCA1ATMCYP2D6CYP2C9
SCHEMBL5162415 0.73 PTPN1 (0.42) PTPRCPGK1PGK2PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US claimed
EP-2057173-B1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2014-02-26 EP disclosed
US-8119617-B2 aSMase inhibitors NOVARTIS AG (CH) 2012-02-21 US disclosed
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US disclosed
EP-2057173-A1 AMIDES AS SPHINGOMYELINE INHIBITORS Novartis AG (CH) 2009-05-13 EP disclosed
WO-2008022771-A1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022482-A1 aSMase inhibitors SMPD1, SMPD3, SMPD2 PTPRC 2840/4885ACP3 296/4885PSMB1 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.